FDA Clears AI for Heart Failure: Unpacking the AiTiALVSD 510(k)

We dive into the FDA's recent clearance of AiTiALVSD, an AI tool that predicts left ventricular systolic dysfunction from a standard 12-lead ECG. We break down the clinical validation numbers, the demographic gaps in the training data, and what this specific 510(k) clearance means for cardiology workflows.

Key points

• AiTiALVSD by Medical AI Co., Ltd. received FDA Class II clearance to support the diagnosis of Left Ventricular Systolic Dysfunction (LVEF less than or equal to 40%) using 12-lead ECG data.
• The deep learning model was trained on 400,339 ECGs from 148,624 patients across 16 hospitals in Korea, and evaluated in a US retrospective study of 22,101 patients.
• In the US performance study, the software demonstrated a sensitivity of 83.7 and a negative predictive value of 97.7, making it a strong potential rule-out tool for clinicians.
• The FDA document explicitly notes a limitation regarding Black or African American subjects, who made up 9.6% of the validation study, noting that specificity was lower in this subgroup.
• The software provides a binary output of High or Low, but the FDA strictly warns it must not be used as a substitute for echocardiography or as a standalone diagnosis.

Source: Re: K254302 - U.S. Food and Drug Administration, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/fda-clears-ai-for-heart-failure-unpacking-the-aitialvsd-510-k-8822ad